ESPE Abstracts (2022) 95 P1-508

ESPE2022 Poster Category 1 Growth and Syndromes (85 abstracts)

Real-world experience with Vosoritide for achondroplasia: interim findings from an early access programme in France

Valérie Cormier-Daire 1 , Shelda Cohen 2 , Thomas Edouard 3 , Bertrand Isidor 4 , Swati Mukherjee 2 , Jeanne Pimenta 2 , Massimiliano Rossi 5 , Elise Schaefer 6 , Sabine Sigaudy 7 & Geneviève Baujat 8

1Reference Center for Skeletal Dysplasia, Paris University, Hopital Necker - Enfants Malades Hopital Necker Enfants Malades, Paris, France; 2BioMarin (U.K.) Limited, London, United Kingdom; 3Endocrine, Bone Diseases and Genetics Unit, Reference Centre for Rare Diseases of Calcium and Phosphate Metabolism, ERN BOND, OSCAR Network, Paediatric Research Unit, Children’s Hospital, Toulouse University Hospital, RESTORE, INSERM U1301, Toulouse, France; 4Centre Hospitalier Universitaire de Nantes, Nantes, France; 5Service de génétique, Hospices Civils de Lyon; INSERM U1028, CNRS UMR5292, CRNl, GENDEV Team, UCBL1, Lyon, France; 6CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France; 7Département de Génétique Médicale, Hôpital Timone Enfant, Marseille, France; 8Hopital Necker - Enfants Malades Hopital Necker Enfants Malades, Paris, France

Introduction: Achondroplasia is caused by a pathogenic mutation in the FGFR3 gene, leading to impaired endochondral bone growth and multiple medical complications. Vosoritide (once daily, subcutaneous injection) has recently been approved by the European Medicines Agency (EMA) for treating achondroplasia in patients aged ≥2 years until closure of epiphyses. It has been made available in France via an early access program, a cohort Temporary Authorization for Use (ATU). We report on the early experiences (baseline clinical characteristics, initiation process and safety) of patients enrolled in the ATU within the French Centre of Reference for skeletal dysplasia (CRMR MOC) network.

Methods: The ATU was initiated on 24th June 2021. A consortium of French achondroplasia experts belonging to the CRMR MOC reviewed the ACH cases followed in the network, to confirm eligibility for treatment initiation. Scale up with prioritization of the oldest patients was proposed, within the children with achondroplasia aged ≥5 years with open epiphyses. After treatment initiation and parent therapeutic education, the patient follow up includes visits at month 1, 3 and 6 and at 6-monthly intervals thereafter. Data are systematically collected to evaluate treatment compliance, adverse events and growth.

Results: The first patient enrolled in the ATU on 27th of September 2021, and at the time of data-cut (13 December 2021), 29 patients were enrolled from 6 centers across France. At the start of treatment (baseline), 52% of patients were female with a mean age of 9 years, ranging between 7 and 13 years. The mean height was 106.9 cm (range 92.0- 119.5 cm) with height z-scores ranging between -3.9 and -7.7 in males and -3.4 and -6.0 in females. Mean weight was 26.2 kg (16.8-60.8kg). No enrolled patients discontinued treatment and compliance was 100% with no patients reporting any missed doses. In total, there were 12 adverse events (AEs) reported among 7 patients. The majority of AEs were mild and included injection site reactions and vomiting, with the most common being injection site rash (4 events). There were no serious adverse events related to vosoritide treatment, and no AEs led to permanent treatment discontinuation.

Conclusions: Over a 3-month period in a real-world setting, the overall safety profile of vosoritide in children with achondroplasia was consistent with that observed in clinical trials. Ongoing monitoring and data collection from this early access program will be useful to establish the ongoing safety and effectiveness of vosoritide in the real world.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.